
Sign up to save your podcasts
Or
Newer oral glucose-lowering agents have revolutionized the treatment of type 2 diabetes (T2D), yet up to 40% of people across the globe still require insulin.
Credit available for this activity expires: 10/18/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/982624?src=mkm_podcast_series_982624
4.3
2323 ratings
Newer oral glucose-lowering agents have revolutionized the treatment of type 2 diabetes (T2D), yet up to 40% of people across the globe still require insulin.
Credit available for this activity expires: 10/18/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/982624?src=mkm_podcast_series_982624
13 Listeners
322 Listeners
98 Listeners
160 Listeners
862 Listeners
496 Listeners
692 Listeners
18 Listeners
272 Listeners
255 Listeners
3,321 Listeners
135 Listeners
1,081 Listeners
7,991 Listeners
186 Listeners
59 Listeners
8 Listeners
423 Listeners
314 Listeners